Skip to main content
Premium Trial:

Request an Annual Quote

Hold the Release

The European Medicines Agency has been moving toward making data submitted to it by drug companies seeking its approval more readily available, but two companies have sued to block the release of their clinical trial data, the Nature News Blog reports.

The EMA's move came after a number of "revelations that high-profile companies have hidden crucial data on safety and efficacy," as Nature News reported in March.

The companies, Illinois-based AbbVie and InterMune in California, took the EMA to court to stop the release of their data. An interim decision from the European General Court has blocked the EMA from releasing the documents, the Nature News Blog now says.

This, the Sense About Science advocacy group adds, may affect the release of other data and documents. "If AbbVie and InterMune win their cases, there is a real chance that EMA's revolution in data transparency will come to an abrupt end, returning us to the old status quo of data secrecy," Johns Hopkins University's Peter Doshi says in a statement from the group.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.